Immunocore

IPO

Pioneers of the world's first approved TCR therapy

Public · Abingdon, Oxon, United Kingdom · $205.0M raised

Headquarters
Abingdon, Oxon
Business Model
B2B
Total Funding
$205.0M
Last Round
$75.0M Series CJan 2021
Rounds
2
Type
Public

About

Immunocore is a commercial-stage biotechnology company that discovered, developed, and commercialized the world's first approved T cell receptor (TCR) therapy, built on its proprietary ImmTAX platform derived from University of Oxford research. The modular platform underpins a pipeline of bispecific immunotherapies spanning oncology, HIV, and HBV, plus autoimmune disease, with partnerships including Genentech, GSK, and the Bill & Melinda Gates Foundation.

Summary

Immunocore is a Healthcare company based in Abingdon, Oxon, United Kingdom. It has raised $205.0M in total across 2 rounds, most recently a $75.0M Series C round in Jan 2021. Investors include Omega Funds and General Atlantic.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOFeb 2021
$297.1M

Sign up to see all 3 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immunocore on Indexed.vc
<a href="https://indexed.vc/companies/immunocore"><img src="https://indexed.vc/api/badge/company/immunocore" alt="Immunocore on Indexed.vc" width="260" height="76" /></a>